At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
everolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Everolimus on HIV Persistence Post Kidney (and Kidney/Pancreas) or Liver Transplant
In Brief
A Phase 4 clinical trial evaluating everolimus for HIV and 2 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Zortress (everolimus), the 40-O-(2-hydroxyethyl)-derivative of rapamycin, is an mTOR inhibitor approved for rejection prophylaxis in kidney transplant recipients. mTOR inhibition may favorably impact the HIV viral reservoir, and we hypothesize that adding everolimus to the transplant immunosuppressive regimen of HIV positive transplant recipients will decrease HIV persistence in CD4+ lymphocytes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Kidney Transplant, Liver Transplant
CountriesUnited States
CollaboratorsamfAR, The Foundation for AIDS Research, Novartis
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartFeb 2016
Primary CompletionJan 2018
TodayJul 2026
First PostedApr 29, 2015
Enrollment StartFeb 24, 2016
Primary CompletionJan 31, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.2 years ago
Interventions
everolimusdrug